A real-world study of Adebrelimab (PD-L1) combined with gemcitabine and cisplatin (GP) in patients with high postoperative recurrence factors of cholangiocarcinoma

A real-world study of Adebrelimab (PD-L1) combined with gemcitabine and cisplatin (GP ) in patients with high postoperative recurrence factors of cholangiocarcinoma

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300078584

Enrollment

Unknown

Registered

2023-12-13

Start date

2023-12-15

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BTC

Interventions

experimental group (Adebrelimab (PD-L1) combined with gemcitabine and cisplatin (GP )):NA

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with cholangiocarcinoma confirmed by imaging and pathology; 2. Having high postoperative recurrence factors and good postoperative recovery; 3. Age = 18; 4. Adequate organ function; 5. No serious complications or contraindications; 6. Patients who receive combination therapy with adelbilimab (PD-L1) and GP.

Exclusion criteria

Exclusion criteria: If a patient has any of the following conditions, they are prohibited from participating in this study: 1. Confirmed pregnant or lactating women; 2. Participating in any research with intervention measures outside of routine clinical practice; 3. The researcher determines other situations that are not suitable for inclusion in the study.

Design outcomes

Primary

Measure	Time frame
Relapse-free survival, RFS;	—

Secondary

Measure	Time frame
OS;Time to Recurrence,TTR;12Y/18Y-RFS %;12Y/18Y-OS%;	—

Countries

China

Contacts

Public ContactZhang Zongli

Qilu Hospital of Shandong University

zzlzzl1900@163.com+86 185 6008 5226

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026